Foundation Medicine to present prostate cancer biomarker study at ESMO 2026
Foundation Medicine will present 12 research abstracts at the ESMO Congress in Madrid on October 23-27, 2026, including two rapid oral presentations on liquid-biopsy findings relevant to prostate cancer treatment selection and prognosis.
1. Research presentations
Foundation Medicine will present 12 research abstracts at the ESMO Congress in Madrid on October 23-27, 2026. Two rapid oral presentations will examine liquid-biopsy findings relevant to prostate cancer treatment selection and prognosis. Other research identifies circulating tumor DNA tumor fraction as a predictor of resistance to systemic therapy across solid tumors.
